Completed PHASE1 INTERVENTIONAL 1-arm NCT01489943

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

Sponsor: GlaxoSmithKline

Conditions Crohn's Disease

Interventions GSK1605786 500 mg Midazolam 3 mg Omeprazole 40 mg Pioglitazone 15 mg Rosuvastatin 10 mg

Updated 7 times since 2017 Last updated: Jul 24, 2017 Started: Sep 19, 2011 Primary completion: Nov 10, 2011 Completion: Nov 10, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01489943, this PHASE1 trial focuses on Crohn's Disease and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2017 — Aug 2017 [monthly]

Completed PHASE1
Jan 2017 — Jun 2017 [monthly]

Completed PHASE1

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States